{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:02:54Z","timestamp":1775232174890,"version":"3.50.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n Long-term follow-up studies regarding the safety of risk-reducing mastectomy (RRM) in terms of cancer risk and surgical complications among women with germline pathogenic variants (gPVs) in\n BRCA1<\/jats:italic>\n or\n BRCA2<\/jats:italic>\n (\n BRCA1\/2<\/jats:italic>\n ) are scarce.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To analyze cancer risk and surgical complications after RRM.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This nationwide cohort study investigated 1208 Swedish women with a confirmed gPV in\n BRCA1\/2<\/jats:italic>\n without previous breast cancer identified through the Swedish Cancer Genetic Units between March 31, 1994, and January 2, 2019. Data were extracted from the National Patient Care Register, the Cancer Register, and the Cause of Death Register. Women were followed up from the date of RRM (RRM group) or genetic testing (no RRM group) until breast cancer diagnosis, death, emigration, or end of follow-up (December 31, 2023).\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Breast cancer incidence was calculated per 10\u202f000 person-years, with women undergoing RRM contributing person-years to the no RRM group until RRM, and women with occult breast cancer contributing breast cancer cases to the no RRM group.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the RRM group (507 women; median age at RRM, 39.7 years [range, 19.6-72.1 years]), 1 woman developed breast cancer, corresponding to a breast cancer incidence of 2 cases per 10\u202f000 person-years. In the no RRM group (701 women; median age at genetic testing, 50.6 years [range, 4.3-93.6 years]), 112 women developed breast cancer, corresponding to a breast cancer incidence of 162 cases per 10\u202f000 person-years. At RRM, 17 of 507 women (3.4%) received a diagnosis of occult breast cancer. In the RRM group, 296 of 507 women (58.4%) underwent simple mastectomy, 143 of 507 (28.2%) underwent nipple-sparing mastectomy, and 68 of 507 (13.4%) underwent skin-sparing mastectomy. Most women (382 of 507 [75.3%]) underwent implant-based breast reconstruction, with only 73 of 507 (14.4%) undergoing autologous tissue reconstruction with or without implants. Early major surgical postoperative complications associated with reoperation occurred in 19 of 507 women (3.7%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this cohort study of 1208 women with a gPV in\n BRCA1\/2<\/jats:italic>\n , the risk of developing breast cancer or early major surgical complications after RRM was very low. The low occurrence of primary breast cancer precluded meaningful statistical comparisons between different RRM techniques.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.2574","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:30:24Z","timestamp":1775230224000},"page":"e262574","source":"Crossref","is-referenced-by-count":0,"title":["Surgical Outcomes After Risk-Reducing Mastectomy Among\n BRCA1<\/i>\n and\n BRCA2<\/i>\n Carriers"],"prefix":"10.1001","volume":"9","author":[{"given":"Rebecca","family":"Wiberg","sequence":"first","affiliation":[{"name":"Department of Diagnostics and Intervention, Plastic Surgery and Surgery, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"H\u00e4gglund","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Plastic Surgery and Surgery, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbro","family":"Numan Hellquist","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Oncology, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ros\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Oncology, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Idahl","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Obstetrics and Gynecology, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Plastic and Reconstructive Surgery, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Bajalica-Lagercrantz","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Genetics and Genomics, Hereditary Cancer Unit, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Ehrencrona","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden"},{"name":"Department of Clinical Genetics, Pathology and Molecular Diagnostics, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Loman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Radiation Physics, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Sund","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Plastic Surgery and Surgery, Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Swedish BRCA Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5ke","family":"Borg","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"\u00d6fverholm","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"von Wachenfeldt","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Edwinsdotter Ardnor","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Kuchinskaya","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Rantala","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylva","family":"Karlsson","sequence":"additional","affiliation":[{"name":"for the Swedish BRCA Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"3","key":"zoi260110r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi260110r2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-017-4584-y","article-title":"BRCAsearch: written pre-test information and BRCA1\/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.","volume":"168","author":"Nilsson","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"zoi260110r4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi260110r5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology.","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"zoi260110r7","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1245\/s10434-015-4532-1","article-title":"Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.","volume":"22","author":"De Felice","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"zoi260110r8","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review.","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"zoi260110r9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/SLA.0b013e318214b55a","article-title":"Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey.","volume":"253","author":"Arver","year":"2011","journal-title":"Ann Surg"},{"issue":"9","key":"zoi260110r10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"zoi260110r11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi260110r12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi260110r13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260110r14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/genes12020253","article-title":"Nipple sparing mastectomy as a risk-reducing procedure for BRCA-mutated patients.","volume":"12","author":"Rocco","year":"2021","journal-title":"Genes (Basel)"},{"issue":"6","key":"zoi260110r15","first-page":"467","article-title":"Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy.","volume":"4","author":"van Verschuer","year":"2015","journal-title":"Gland Surg"},{"issue":"20","key":"zoi260110r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"zoi260110r20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/bjs.6930","article-title":"Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score.","volume":"97","author":"Armitage","year":"2010","journal-title":"Br J Surg"},{"issue":"5","key":"zoi260110r21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3414\/ME17-01-0051","article-title":"The Charlson Comorbidity Index in registry-based research.","volume":"56","author":"Brusselaers","year":"2017","journal-title":"Methods Inf Med"},{"issue":"21","key":"zoi260110r22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.","volume":"93","author":"Hartmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi260110r23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002748.pub4","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer.","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi260110r24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41416-023-02503-8","article-title":"Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.","volume":"130","author":"Metcalfe","year":"2024","journal-title":"Br J Cancer"},{"issue":"3","key":"zoi260110r25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"zoi260110r26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1245\/s10434-019-07259-1","article-title":"Prospective evaluation of residual breast tissue after skin- or nipple-sparing mastectomy: results of the SKINI-trial.","volume":"26","author":"Papassotiropoulos","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"zoi260110r27","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1245\/s10434-015-4739-1","article-title":"Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review.","volume":"22","author":"De La Cruz","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"zoi260110r28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/bjs.11616","article-title":"Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.","volume":"107","author":"Valero","year":"2020","journal-title":"Br J Surg"},{"issue":"3","key":"zoi260110r29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-018-4937-1","article-title":"Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy.","volume":"172","author":"Weber","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi260110r30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1245\/s10434-014-3883-3","article-title":"Nipple-sparing mastectomy in BRCA1\/2 mutation carriers: an interim analysis and review of the literature.","volume":"22","author":"Yao","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"zoi260110r31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamasurg.2017.3422","article-title":"Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study.","volume":"153","author":"Jakub","year":"2018","journal-title":"JAMA Surg"},{"issue":"2","key":"zoi260110r32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jmedgenet-2020-107356","article-title":"Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.","volume":"59","author":"Marcinkute","year":"2022","journal-title":"J Med Genet"},{"issue":"1","key":"zoi260110r33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/curroncol31010023","article-title":"Counselling framework for germline BRCA1\/2 and PALB2 carriers considering risk-reducing mastectomy.","volume":"31","author":"Wong","year":"2024","journal-title":"Curr Oncol"},{"issue":"4","key":"zoi260110r34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281601","article-title":"Bilateral risk-reducing mastectomy and reconstruction\u2014a 12-year review of methodological trends and outcomes at a tertiary referral centre.","volume":"18","author":"Aslam","year":"2023","journal-title":"PLoS One"},{"issue":"10","key":"zoi260110r35","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1245\/s10434-019-07560-z","article-title":"Outcomes of >1300 nipple-sparing mastectomies with immediate reconstruction: the impact of expanding indications on complications.","volume":"26","author":"Young","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"zoi260110r36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/2000656X.2018.1470093","article-title":"Complications, risk factors, and patients-reported outcomes after skin-sparing mastectomy followed by breast reconstruction in women with BRCA mutations.","volume":"52","author":"Moberg","year":"2018","journal-title":"J Plast Surg Hand Surg"},{"key":"zoi260110r37","doi-asserted-by":"publisher","DOI":"10.21037\/abs.2019.11.01","article-title":"Twenty-five years of risk-reducing mastectomies and immediate breast reconstruction\u2014lessons learned from a single institution.","author":"Sandelin","year":"2019","journal-title":"Ann Breast Surg"},{"issue":"1","key":"zoi260110r38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1186\/s12885-018-4912-6","article-title":"Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.","volume":"18","author":"Geers","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi260110r39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1245\/s10434-015-4709-7","article-title":"Skin flap necrosis after mastectomy with reconstruction: a prospective study.","volume":"23","author":"Matsen","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"zoi260110r40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/bjs\/znad107","article-title":"Strategies to avoid mastectomy skin-flap necrosis during nipple-sparing mastectomy.","volume":"110","author":"Moo","year":"2023","journal-title":"Br J Surg"},{"issue":"12","key":"zoi260110r41","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.pec.2017.06.032","article-title":"A systematic review of women\u2019s satisfaction and regret following risk-reducing mastectomy.","volume":"100","author":"Braude","year":"2017","journal-title":"Patient Educ Couns"},{"key":"zoi260110r3","author":"Boyle"},{"key":"zoi260110r6","unstructured":"National Care Program Breast Cancer. Confederation of Regional Cancer Centres in Sweden. Updated November 11, 2025. Accessed November 18, 2025. https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/brostcancer\/vardprogram\/"},{"key":"zoi260110r17","unstructured":"National Patient Register. The National Board of Health and Welfare. Updated January 12, 2026. Accessed January 29, 2026. https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/patientregistret\/"},{"key":"zoi260110r18","unstructured":"National Cancer Register. The National Board of Health and Welfare. Updated December 19, 2024. Accessed January 29, 2026. https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/cancerregistret\/"},{"key":"zoi260110r19","unstructured":"National Cause of Death Register. The National Board of Health and Welfare. Updated February 9, 2024. Accessed January 29, 2026. https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-cause-of-death--register\/"},{"key":"zoi260110r42","unstructured":"Arvidsson? G. Statistical register\u2019s production and quality: National Cancer Register. Version 1. The Swedish National Board of Health and Welfare. Updated March 17, 2023. Accessed January 29, 2026. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/dokument-webb\/ovrigt\/production-and-quality-can.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847293\/wiberg_2026_oi_260110_1774651691.87908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:30:25Z","timestamp":1775230225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.2574","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}